CClinicalTrials.gg
Active, not recruitingNCT05328180DELICATEUpdated Sep 16, 2025

aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE)

An interventional study of Sodium bicarbonate and Control arm in Carpal Tunnel Syndrome, sponsored by Kuopio University Hospital. Active, not recruiting at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Kuopio University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction Carpal tunnel syndrome (CTS) is the most common peripheral nerve entrapment syndrome in Finland and worldwide. Nowadays carpal tunnel release (CTR) surgery is often done in local anaesthesia. Often the most painful event during CTR is the injection of the local anaesthetic. Multiple different methods have been trialed and buffering the local anaesthetic seems to have good results in reducing the pain caused by the injection. However, no study has buffered long-acting local anaesthetic in CTR surgery, and no study has accounted for the patient's individual pain tolerance in the groups. There are no comparisons of the results to minimal clinically important difference (MCID) for pain.

Hypothesis In this study the investigators will evaluate the effects of buffering long-lasting local anaesthetic in wide-awake local anaesthesia no tourniquet (WALANT) CTR. This study's hypothesis is that buffering long-acting local anaesthetic with sodium bicarbonate decreases the pain of the injection.

The investigators also expect that buffering will reduce the number of needle stings felt during injection, will result in as good perioperative pain control, will lengthen the effect of anaesthetic, will reduce postoperative painkiller usage, will have at least as good functional outcome and greater patient satisfaction.

Methods This study will enlist 116 patients and divide the patients into two groups in this double blinded randomized controlled trial. One group receives non-buffered, and the second group buffered local anaesthetic. This study's primary outcome is to compare burning, pressure, needle sting and total pain the patient experienced between the groups. The investigators will assess this using VAS, and will compare the results to MCID. The investigators secondary outcomes are comparisons of expected injection pain level and pain during CTR with VAS, individual pain tolerance/catastrophising tendency with preoperative PCS-FINv2.0 form, the number of needle stings the patient feels during the injection, functional outcome and improvement of the patients' symptoms with The Boston Carpal Tunnel Questionnaire (Likert 5) before and after the surgery, evaluation of patient satisfaction with net promoter score (NPS) and the use of painkillers, duration of analgesia and pain levels using VAS after the surgery until the 3rd postoperative night.

02

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • Carpal Tunnel Release
  • Bicarbonate
  • Local anaesthesia
  • Wide awake lidocain cum adrenalin no tourniquet
  • Pain
  • Carpal tunnel syndrome
03

In context

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.

This study's enrollment of 116 is above the median of 60 across 445 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Kuopio University Hospital is the lead sponsor of 132 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinically and electrophysiologically diagnosed carpal tunnel syndrome
  • Patients who are scheduled for carpal tunnel release surgery.

Exclusion criteria

Exclusion Criteria:

  • Associated disease or conditions, including earlier injury to median nerve, cervical radiculopathy, cubital tunnel syndrome and other peripheral neuropathy
  • Chronic renal failure
  • Rheumatoid arthritis
  • Allergies to lidocaine
  • Pregnancy
  • Profound cognitive impairment
  • Previous ipsilateral carpal tunnel decompression
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Other
    Non-buffered local anaesthetic

    The investigators allocate 58 patients in this arm. It serves as the control group, who receives currently used local anaesthetic solution.

    Other: Control arm

  • Experimental
    Buffered local anaesthetic

    The investigators allocate 58 patients in this arm. It serves as the experimental group, who receives currently used anaesthetic solution that has been buffered.

    Other: Sodium bicarbonate

Interventions

  • OtherSodium bicarbonate

    A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.

  • OtherControl arm

    A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.

06

What researchers measure

Primary outcomes

  1. Total pain level with visual analogic scale (VAS)

    The investigators evaluate the total pain with 0-100 mm visual analogue scale (VAS). In VAS higher number means more pain and is therefore worse. The investigators calculate the mean VAS level for each group and compare the results to find statistically and clinically relevant difference. Clinically relevant difference is evaluated by comparing the VAS difference to MCID.

    Time frame: VAS is recorded immediately after the injection of local anaesthetic.

Secondary outcomes

  1. Burning pain level with VAS

    The investigators evaluate the total pain with 0-100 mm visual analogue scale (VAS). In VAS higher number means more pain and is therefore worse.

    Time frame: VAS is recorded immediately after the injection of local anaesthetic.

  2. Pressure pain level with VAS

    The investigators evaluate the total pain with 0-100 mm visual analogue scale (VAS). In VAS higher number means more pain and is therefore worse.

    Time frame: VAS is recorded immediately after the injection of local anaesthetic.

  3. Needle sting pain level with VAS

    The investigators evaluate the total pain with 0-100 mm visual analogue scale (VAS). In VAS higher number means more pain and is therefore worse.

    Time frame: VAS is recorded immediately after the injection of local anaesthetic.

  4. CTR pain level

    The investigators evaluate the maximum pain level patient experiences during CTR surgery with visual analogue scale (VAS). This study uses 0-100 mm VAS. In VAS higher number means more pain and is therefore worse.

    Time frame: VAS is recorded right after CTR surgery

  5. Analgesia duration

    The investigators assess the length of the anaesthesia by recording the pain level with visual analogue scale (VAS) every 4 hours. This study uses 0-100 mm VAS. In VAS higher number means more pain and is therefore worse.

    Time frame: Every 4 hours after the surgery until 3rd postoperative night.

  6. Painkiller consumption

    The investigators record the painkiller consumption after the surgery.

    Time frame: After the surgery until 3rd postoperative night.

  7. Number of needle stings

    The investigators ask the patient to report how many needle stings the patient felt during the injection of the local anaesthetic.

    Time frame: Immediately after the injection of local anaesthetic.

  8. Pain catastrophizing tendency

    The investigators ask the patients to fill pain catastrophizing tendency evaluating form (PCS-FINv2.0) before the surgery in order to evaluate the pain levels between the experimental and control group. It has 13 questions and scores between 0-52. Higher score means higher pain catastrophizing tendency.

    Time frame: Before the surgery.

  9. Functional outcome

    The investigators ask the patients to evaluate symptoms and functional outcome using the Boston Carpal Tunnel Questionnaire (BTCQ). It has 11 questions for symptoms of carpal tunnel syndrome and scores between 11 and 55. Higher score means more symptoms. BTCQ also has 8 questions for functionality of hand and it has scores between 8 and 40. Higher scores mean worse function of the hand.

    Time frame: Before and 3 months after the surgery.

  10. Patient satisfaction

    The investigators ask the patients to evaluate the surgery experience with net promoter score (NPS). NPS has 10 steps and higher value indicates greater satisfaction.

    Time frame: 3 months after the surgery.

  11. Expected pain level

    The investigators ask the patients to evaluate the pain the patient expect to experience during administration of local anaesthetic using visual analogue scale (VAS). This study uses 0-100 mm VAS. In VAS higher number means more pain and is therefore worse.

    Time frame: Before the surgery.

07

Study locations

1 site
  • Kuopio University hospital, Department of Orthopaedics, Traumatology and Hand Surgery
    Kuopio, Northern Savonia 70029, Finland
08

References and documents

Publications

  • Hytonen M, Nietosvaara Y, Reito A, Sirola J, Heikkinen N, Savolainen A, Raisanen MP. Protocol for a double-blinded randomised controlled trial investigating the use of adjunct bicarbonate in carpal tunnel release: a single-centre study. BMJ Open. 2023 Sep 18;13(9):e071488. doi: 10.1136/bmjopen-2022-071488. PubMed 37723109 ↗

Study documents

  • Informed consent form · Jan 28, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — The investigators share pseudonymised data in EU/ETA if it is separately requested.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05328180
Lead sponsor
Kuopio University Hospital
Collaborators
University of Eastern Finland
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Sep 21, 2022
Primary completion
Jun 30, 2025
Completion
Dec 2025 (estimated)
Last update
Sep 16, 2025

Study contacts

Yrjänä Nietosvaara, Prof.
study director · Kuopio University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion